1
|
Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S, Böttcher JP. PGE 2 limits effector expansion of tumour-infiltrating stem-like CD8 + T cells. Nature 2024:10.1038/s41586-024-07254-x. [PMID: 38658748 DOI: 10.1038/s41586-024-07254-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Accepted: 02/28/2024] [Indexed: 04/26/2024]
Abstract
Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer immunity through expansion and effector cell differentiation1-4; however, this response is dysfunctional in tumours. Current cancer immunotherapies2,5-9 can promote anticancer responses through TCF1+ stem-like CD8+ T cells in some but not all patients. This variation points towards currently ill-defined mechanisms that limit TCF1+CD8+ T cell-mediated anticancer immunity. Here we demonstrate that tumour-derived prostaglandin E2 (PGE2) restricts the proliferative expansion and effector differentiation of TCF1+CD8+ T cells within tumours, which promotes cancer immune escape. PGE2 does not affect the priming of TCF1+CD8+ T cells in draining lymph nodes. PGE2 acts through EP2 and EP4 (EP2/EP4) receptor signalling in CD8+ T cells to limit the intratumoural generation of early and late effector T cell populations that originate from TCF1+ tumour-infiltrating CD8+ T lymphocytes (TILs). Ablation of EP2/EP4 signalling in cancer-specific CD8+ T cells rescues their expansion and effector differentiation within tumours and leads to tumour elimination in multiple mouse cancer models. Mechanistically, suppression of the interleukin-2 (IL-2) signalling pathway underlies the PGE2-mediated inhibition of TCF1+ TIL responses. Altogether, we uncover a key mechanism that restricts the IL-2 responsiveness of TCF1+ TILs and prevents anticancer T cell responses that originate from these cells. This study identifies the PGE2-EP2/EP4 axis as a molecular target to restore IL-2 responsiveness in anticancer TILs to achieve cancer immune control.
Collapse
Affiliation(s)
- Sebastian B Lacher
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Janina Dörr
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Gustavo P de Almeida
- Division of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, TUM, Freising, Germany
| | - Julian Hönninger
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
- Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, TUM, Munich, Germany
| | - Felix Bayerl
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Anna Hirschberger
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Anna-Marie Pedde
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Philippa Meiser
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Lukas Ramsauer
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Thomas J Rudolph
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Nadine Spranger
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Matteo Morotti
- Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland
- Department of Oncology, University Hospital of Lausanne (CHUV) and UNIL, Lausanne, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Alizee J Grimm
- Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland
- Department of Oncology, University Hospital of Lausanne (CHUV) and UNIL, Lausanne, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Sebastian Jarosch
- Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, TUM, Munich, Germany
- Boehringer Ingelheim, Biberach, Germany
| | - Arman Oner
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Lisa Gregor
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Stefanie Lesch
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Stefanos Michaelides
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Luisa Fertig
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Daria Briukhovetska
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Lina Majed
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
| | - Sophia Stock
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital, Munich, Germany
| | - Dirk H Busch
- Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, TUM, Munich, Germany
| | - Veit R Buchholz
- Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, TUM, Munich, Germany
| | - Percy A Knolle
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
| | - Dietmar Zehn
- Division of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, TUM, Freising, Germany
| | - Denarda Dangaj Laniti
- Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland
- Department of Oncology, University Hospital of Lausanne (CHUV) and UNIL, Lausanne, Switzerland
- Agora Cancer Research Center, Lausanne, Switzerland
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, Member of the German Center for Lung Research (DZL), LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU University Hospital, Munich, Germany
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Munich, Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Jan P Böttcher
- Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
| |
Collapse
|
2
|
Stock S, Fertig L, Gottschlich A, Dörr J, Märkl F, Majed L, Menkhoff VD, Grünmeier R, Rejeski K, Cordas Dos Santos DM, Theurich S, von Bergwelt-Baildon M, Endres S, Subklewe M, Kobold S. Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma. Cancer Immunol Immunother 2024; 73:100. [PMID: 38630291 DOI: 10.1007/s00262-024-03688-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2023] [Accepted: 03/22/2024] [Indexed: 04/19/2024]
Abstract
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as intracellular costimulatory domain are in routine clinical use. As the CAR construct architecture can differentially impact performance and efficacy, the optimal construction of a BCMA-targeting CAR remains to be elucidated. Here, we hypothesized that varying the constituents of the CAR structure known to impact performance could shed light on how to improve established anti-BCMA CAR constructs. CD8TM.41BBIC-based anti-BCMA CAR vectors with either a long linker or a short linker between the light and heavy scFv chain, CD28TM.41BBIC-based and CD28TM.CD28IC-based anti-BCMA CAR vector systems were used in primary human T cells. MM cell lines were used as target cells. The short linker anti-BCMA CAR demonstrated higher cytokine production, whereas in vitro cytotoxicity, T cell differentiation upon activation and proliferation were superior for the CD28TM.CD28IC-based CAR. While CD28TM.CD28IC-based CAR T cells killed MM cells faster, the persistence of 41BBIC-based constructs was superior in vivo. While CD28 and 41BB costimulation come with different in vitro and in vivo advantages, this did not translate into a superior outcome for either tested model. In conclusion, this study showcases the need to study the influence of different CAR architectures based on an identical scFv individually. It indicates that current scFv-based anti-BCMA CAR with clinical utility may already be at their functional optimum regarding the known structural variations of the scFv linker.
Collapse
Affiliation(s)
- Sophia Stock
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany.
| | - Luisa Fertig
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
| | - Adrian Gottschlich
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
| | - Janina Dörr
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
| | - Florian Märkl
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
| | - Lina Majed
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
| | - Vivien D Menkhoff
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
| | - Ruth Grünmeier
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
| | - Kai Rejeski
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
- Laboratory of Translational Cancer Immunology, LMU Gene Center, Munich, Germany
| | - David M Cordas Dos Santos
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
- Cancer- and Immunometabolism Research Group, LMU Gene Center, Munich, Germany
| | - Sebastian Theurich
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
- Cancer- and Immunometabolism Research Group, LMU Gene Center, Munich, Germany
| | - Michael von Bergwelt-Baildon
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
| | - Stefan Endres
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Marion Subklewe
- Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany
- Laboratory of Translational Cancer Immunology, LMU Gene Center, Munich, Germany
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, a partnership between the DKFZ Heidelberg and the LMU University Hospital, Munich, Germany.
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
| |
Collapse
|
3
|
Al-Mohannadi AS, Farooq A, Salman A, Ghram A, Al-Harahsheh ST, Majed L, Sayegh S, Cardinale M. The effects of the first wave of COVID-19 restrictions on physical activity: a longitudinal study from "step into health" program in Qatar. Front Public Health 2024; 12:1333546. [PMID: 38510355 PMCID: PMC10951068 DOI: 10.3389/fpubh.2024.1333546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Accepted: 02/07/2024] [Indexed: 03/22/2024] Open
Abstract
Introduction The COVID-19 pandemic led to restrictions that prevented physical activity in public places. This study sought to conduct a comprehensive longitudinal analysis of how lockdown policies in an Arabian Gulf country influenced the patterns of physical activity during first wave. Methods In a longitudinal study design, members of the ongoing "Step into health" community-based health promotion program who provided valid pedometer data from January to August 2020, covering pre, during and post-covid first wave period met the inclusion criteria. Results 420 (76.7% men, 13.8% ≤40 years) were included in the study. Overall, significant decline in daily step counts was recorded (-1,130 ± SE302) after the implementation of lockdown policies (p < 0.001). When the restrictions were removed, the steps per day were still lower compared to pre-covid for men (-910 ± SE610, p = 0.017) and among individuals with normal BMI (-1,304 ± SE409, p = 0.004). The lockdown in Qatar did not significantly affect women and individuals with obesity who already had lower daily steps pre-covid. Discussion The present study confirms immediate decline in daily steps imposed indirectly through the COVID-19 lockdown measures. Participants with higher physical activity levels pre-covid experienced significant decline in step count during and even after restrictions were uplifted.
Collapse
Affiliation(s)
| | - Abdulaziz Farooq
- Aspetar, Orthopaedic and Sports Medicine Hospital, Research and Scientific Support, Doha, Qatar
| | - Ahmad Salman
- Department of Public Health Practice, Kuwait University, Safat, Kuwait
- Department of Physical Education, College of Education, Qatar University, Doha, Qatar
| | - Amine Ghram
- Department of Cardiac Rehabilitation, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
- Research Laboratory "Heart Failure, LR12SP09", Hospital Farhat HACHED of Sousse, Sousse, Tunisia
- Healthy Living for Pandemic Event Protection (Hl-Pivot) Network, Chicago, IL, United States
| | | | - Lina Majed
- College of Health and Life Sciences, Qatar Foundation, Hamad Bin Khalifa University, Doha, Qatar
| | - Suzan Sayegh
- Modern University for Business and Science, Beirut, Lebanon
| | - Marco Cardinale
- Aspetar, Orthopaedic and Sports Medicine Hospital, Research and Scientific Support, Doha, Qatar
- Department of Targeted Intervention, University College London, London, United Kingdom
- Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, United Kingdom
| |
Collapse
|
4
|
Majed L, Ibrahim R, Lock MJ, Jabbour G. Walking around the preferred speed: examination of metabolic, perceptual, spatiotemporal and stability parameters. Front Physiol 2024; 15:1357172. [PMID: 38405123 PMCID: PMC10884095 DOI: 10.3389/fphys.2024.1357172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Accepted: 01/30/2024] [Indexed: 02/27/2024] Open
Abstract
Walking is the most accessible and common type of physical activity. Exercising at one's self-selected intensity could provide long-term benefits as compared to following prescribed intensities. The aim of this study was to simultaneously examine metabolic, perceptual, spatiotemporal and stability parameters at an absolute 3 km·h-1 speed range around the individual preferred walking speed (PWS). Thirty-four young sedentary adults (18 women) volunteered to walk at seven speeds relative to their PWS in 3-min trials interspaced with 3-min rest intervals. Results indicated a significant main effect of speed on all studied variables. While metabolic, perceptual and spatiotemporal values were sensitive to the smallest change in speed (i.e., 0.5 km·h-1), a significant increase in the rate of carbohydrate oxidation and decrease in %fat oxidation were only observed at speeds above PWS. Results also revealed significantly higher coefficients of variation for stride characteristics at speeds below PWS only. Moreover, analyses of best fit models showed a quadratic relationship between most variables and speed, with the exceptions of metabolic cost of transport, rating of perceived exertion and stride duration that changed exponentially with speed. PWS coincided with optimized mechanical efficiency, fuel oxidation and gait stability. This indicated that walking below PWS decreased both mechanical efficiency and stability of gait, while walking above PWS increased carbohydrate oxidation. Those factors seem to play an important role as determinants of PWS. We suggest that walking at PWS may provide benefits in terms of fat oxidation while optimizing gait stability.
Collapse
Affiliation(s)
- Lina Majed
- Exercise Science, Health and Epidemiology Division, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
| | - Rony Ibrahim
- Physical Education Department, College of Education, Qatar University, Doha, Qatar
| | - Merilyn Jean Lock
- Exercise Science, Health and Epidemiology Division, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
| | - Georges Jabbour
- Physical Education Department, College of Education, Qatar University, Doha, Qatar
| |
Collapse
|
5
|
Lorenzini T, Cadilha BL, Obeck H, Benmebarek MR, Märkl F, Michaelides S, Strzalkowski T, Briukhovetska D, Müller PJ, Nandi S, Winter P, Majed L, Grünmeier R, Seifert M, Rausch S, Feuchtinger T, Endres S, Kobold S. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy. Br J Cancer 2023; 129:696-705. [PMID: 37400680 PMCID: PMC10421897 DOI: 10.1038/s41416-023-02332-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 05/25/2023] [Accepted: 06/19/2023] [Indexed: 07/05/2023] Open
Abstract
BACKGROUND In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a tool to convert suppressive signals into stimulation and thus promote the persistence of T cells, but no universal IFP design has been established so far. We now took advantage of a PD-1-CD28 IFP as a clinically relevant structure to define key determinants of IFP activity. METHODS We compared different PD-1-CD28 IFP variants in a human leukemia model to assess the impact of distinctive design choices on CAR T cell performance in vitro and a xenograft mouse model. RESULTS We observed that IFP constructs that putatively exceed the extracellular length of PD-1 induce T-cell response without CAR target recognition, rendering them unsuitable for tumour-specific therapy. IFP variants with physiological PD-1 length ameliorated CAR T cell effector function and proliferation in response to PD-L1+ tumour cells in vitro and prolonged survival in vivo. Transmembrane or extracellular CD28 domains were found to be replaceable by corresponding PD-1 domains for in vivo efficacy. CONCLUSION PD-1-CD28 IFP constructs must mimic the physiological interaction of PD-1 with PD-L1 to retain selectivity and mediate CAR-conditional therapeutic activity.
Collapse
Affiliation(s)
- Theo Lorenzini
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Bruno L Cadilha
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Hannah Obeck
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Mohamed-Reda Benmebarek
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
- National Cancer Institute (NCI), Bethesda, MD, USA
| | - Florian Märkl
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Stefanos Michaelides
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Thaddäus Strzalkowski
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Daria Briukhovetska
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Philipp Jie Müller
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Sayantan Nandi
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Pia Winter
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Lina Majed
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Ruth Grünmeier
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Matthias Seifert
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Svenja Rausch
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
| | - Tobias Feuchtinger
- Department of Pediatric Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Dr. von Hauner University Children's Hospital, LMU University Hospital, LMU, Munich, Germany
- German Center for Infection Research (DZIF), Munich, Germany
| | - Stefan Endres
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany
- German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Germany, Member of the German Center for Lung Research (DZL), Munich, Germany.
- German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany.
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
| |
Collapse
|
6
|
Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma. J Immunother Cancer 2023; 11:jitc-2022-006436. [PMID: 37208128 DOI: 10.1136/jitc-2022-006436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/16/2023] [Indexed: 05/21/2023] Open
Abstract
BACKGROUND Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has shown promising efficacy in melanoma treatment after ICB failure, indicating the potential of cellular therapies. However, TIL treatment comes with manufacturing limitations, product heterogeneity, as well as toxicity problems, due to the transfer of a large number of phenotypically diverse T cells. To overcome said limitations, we propose a controlled adoptive cell therapy approach, where T cells are armed with synthetic agonistic receptors (SAR) that are selectively activated by bispecific antibodies (BiAb) targeting SAR and melanoma-associated antigens. METHODS Human as well as murine SAR constructs were generated and transduced into primary T cells. The approach was validated in murine, human and patient-derived cancer models expressing the melanoma-associated target antigens tyrosinase-related protein 1 (TYRP1) and melanoma-associated chondroitin sulfate proteoglycan (MCSP) (CSPG4). SAR T cells were functionally characterized by assessing their specific stimulation and proliferation, as well as their tumor-directed cytotoxicity, in vitro and in vivo. RESULTS MCSP and TYRP1 expression was conserved in samples of patients with treated as well as untreated melanoma, supporting their use as melanoma-target antigens. The presence of target cells and anti-TYRP1 × anti-SAR or anti-MCSP × anti-SAR BiAb induced conditional antigen-dependent activation, proliferation of SAR T cells and targeted tumor cell lysis in all tested models. In vivo, antitumoral activity and long-term survival was mediated by the co-administration of SAR T cells and BiAb in a syngeneic tumor model and was further validated in several xenograft models, including a patient-derived xenograft model. CONCLUSION The SAR T cell-BiAb approach delivers specific and conditional T cell activation as well as targeted tumor cell lysis in melanoma models. Modularity is a key feature for targeting melanoma and is fundamental towards personalized immunotherapies encompassing cancer heterogeneity. Because antigen expression may vary in primary melanoma tissues, we propose that a dual approach targeting two tumor-associated antigens, either simultaneously or sequentially, could avoid issues of antigen heterogeneity and deliver therapeutic benefit to patients.
Collapse
Affiliation(s)
- Florian Märkl
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Mohamed-Reda Benmebarek
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Julius Keyl
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Bruno L Cadilha
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Martina Geiger
- Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland
| | - Clara Karches
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Hannah Obeck
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Melanie Schwerdtfeger
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Stefanos Michaelides
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Daria Briukhovetska
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Sophia Stock
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
- Department of Medicine III, Klinikum der Universität München, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
| | - Jakob Jobst
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Philipp Jie Müller
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Lina Majed
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Matthias Seifert
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Anna-Kristina Klüver
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Theo Lorenzini
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Ruth Grünmeier
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Moritz Thomas
- Institute of AI for Health, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Freising, Germany
| | - Adrian Gottschlich
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Richard Klaus
- Division of Pediatric Nephrology, Department of Pediatrics, Dr. v. Haunersches Kinderspital, Klinikum der Universität München, Munich, Germany
| | - Carsten Marr
- Institute of AI for Health, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
- Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - Michael von Bergwelt-Baildon
- Department of Medicine III, Klinikum der Universität München, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
| | - Simon Rothenfusser
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Mitchell P Levesque
- Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland
| | - Markus Vincent Heppt
- Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - Stefan Endres
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - Christian Klein
- Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland
| | - Sebastian Kobold
- Department of Medicine IV, Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
- German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany
| |
Collapse
|
7
|
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity 2023; 56:143-161.e11. [PMID: 36630913 PMCID: PMC9839367 DOI: 10.1016/j.immuni.2022.12.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Revised: 09/28/2022] [Accepted: 12/13/2022] [Indexed: 01/12/2023]
Abstract
Although T cells can exert potent anti-tumor immunity, a subset of T helper (Th) cells producing interleukin-22 (IL-22) in breast and lung tumors is linked to dismal patient outcome. Here, we examined the mechanisms whereby these T cells contribute to disease. In murine models of lung and breast cancer, constitutional and T cell-specific deletion of Il22 reduced metastases without affecting primary tumor growth. Deletion of the IL-22 receptor on cancer cells decreases metastasis to a degree similar to that seen in IL-22-deficient mice. IL-22 induced high expression of CD155, which bound to the activating receptor CD226 on NK cells. Excessive activation led to decreased amounts of CD226 and functionally impaired NK cells, which elevated the metastatic burden. IL-22 signaling was also associated with CD155 expression in human datasets and with poor patient outcomes. Taken together, our findings reveal an immunosuppressive circuit activated by T cell-derived IL-22 that promotes lung metastasis.
Collapse
Affiliation(s)
- Daria Briukhovetska
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Javier Suarez-Gosalvez
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Cornelia Voigt
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Anamarija Markota
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Anastasios D. Giannou
- Section of Molecular Immunology and Gastroenterology, I. Department of Medicine, and Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany,Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Maryam Schübel
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Jakob Jobst
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Tao Zhang
- Section of Molecular Immunology and Gastroenterology, I. Department of Medicine, and Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Janina Dörr
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Florian Märkl
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Lina Majed
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Philipp Jie Müller
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Peter May
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Adrian Gottschlich
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Nicholas Tokarew
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Jöran Lücke
- Section of Molecular Immunology and Gastroenterology, I. Department of Medicine, and Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany,Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Arman Oner
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Melanie Schwerdtfeger
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - David Andreu-Sanz
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Ruth Grünmeier
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Matthias Seifert
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Stefanos Michaelides
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Michael Hristov
- Institute for Cardiovascular Prevention (IPEK), University Hospital, Klinikum der Universität München, Munich, Germany
| | - Lars M. König
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | - Bruno Loureiro Cadilha
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany
| | | | - Hans-Joachim Anders
- Division of Nephrology, Department of Medicine IV, Klinikum der Universität München, 80337 Munich, Germany
| | - Simon Rothenfusser
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany,Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), 85764 Neuherberg, Germany
| | - Richard A. Flavell
- Department of Immunobiology, School of Medicine, Yale University, New Haven, CT 06520, USA,Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520, USA
| | - Daniela Cerezo-Wallis
- Melanoma Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
| | - Cristina Tejedo
- Melanoma Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
| | - María S. Soengas
- Melanoma Laboratory, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
| | - Tobias Bald
- Institute of Experimental Oncology, Medical Faculty, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany
| | - Samuel Huber
- Section of Molecular Immunology and Gastroenterology, I. Department of Medicine, and Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - Stefan Endres
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany,Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), 85764 Neuherberg, Germany,Center for Translational Cancer Research (DKTK), Partner Site Munich, 80336 Munich, Germany
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Klinikum der Universität München, 80337 Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), 85764 Neuherberg, Germany; Center for Translational Cancer Research (DKTK), Partner Site Munich, 80336 Munich, Germany.
| |
Collapse
|
8
|
Abi Nader P, Hadla R, Majed L, Mattar L, Sayegh S. Results from the Lebanese 2022 report card on physical activity for children and youth. J Exerc Sci Fit 2023; 21:14-19. [PMID: 36349302 PMCID: PMC9634469 DOI: 10.1016/j.jesf.2022.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 10/18/2022] [Accepted: 10/20/2022] [Indexed: 11/06/2022] Open
Abstract
Objective The Lebanese Active Healthy Kids Work Group (LAHKWG) synthesized literature published on physical activity (PA) indicators among ages 5- to 17- year-olds, using a recommended harmonized process by the Active Healthy Kids Global Alliance (AHKGA), to explore Lebanon's performance since its previous report card publication. Methods Peer reviewed literature, national surveys, and gray literature published since 2017, on 10 common AHKGA and two LAHKWG recommended indicators were examined. Common indicators included overall PA, organized sport and PA, active play, active transportation, community and environment, sedentary behaviors, physical fitness, family and peers, school, and government. LAHKWG recommended indicators were sleep and weight status. LAHKWG members reviewed 764 records, of which 28 were selected for full review. A grade was assigned for each indicator using AHKGA's grading rubric and established benchmarks on data from nationally representative samples for children and youth. Results Data from one nationally representative sample were available for ages 13–17 years (i.e., no data <13 years). Five indicators received “Incomplete” (organized sport and PA; active Play; physical fitness; family and peers; community and environment); overall PA received a D-; active transportation and sleep received a D+; school and government received a D; sedentary behaviors received a C; and weight status received a B-. Conclusion The LAHKWG strongly encourages stakeholders to take concrete actions towards prioritizing PA promotion at a national level especially in the education sector. Offering more quality PA opportunities for Lebanese children and youth will be beneficial for their physical and mental health in any context.
Collapse
|
9
|
Chrismas BCR, Majed L, Al-Mohannadi AS, Sayegh S. Adherence and retention to the self-managed community-based Step Into Health program in Qatar (2012-2019). Front Public Health 2022; 10:927386. [PMID: 36199850 PMCID: PMC9527577 DOI: 10.3389/fpubh.2022.927386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Accepted: 08/15/2022] [Indexed: 01/24/2023] Open
Abstract
Purpose Investigate adherence and retention to the "Step Into Health (SIH)" initiative (www.stepintohealth.qa [website access only available from within the State of Qatar]), a Qatari self-managed community-based health program, from 2012 to 2019. Methods Participants (16,711; 16-80 years; 37% females, 34% Qatari) used a pedometer or smartphone application (app) to measure step count. Absolute adherence (ADH) and retention (RET) were calculated, with ADH (%) the ratio between number of days data and SIH enrollment length (RET). Linear Mixed Models identified differences in ADH between RET groups, main effects (i.e., sex, device, age, BMI, nationality) and interaction effects for ADH (RET entered as a covariate). Results Average ADH and RET to SIH (irrespective of sex, age, device and BMI) was 50% (±31%), and 16% (±20%), respectively, with ADH differing significantly between RET groups (F = 460.2, p < 0.001). RET (as a covariate) revealed a significant main effect for device (F = 12.00, p < 0.001) and age (F = 4.31, p = 0.001) on ADH observed. There was a significant association between RET and sex (p < 0.001), device (p < 0.001), and age groups 16-25 y (p < 0.001), and 26-35 y (p < 0.001). There were no significant main effects for sex or BMI on ADH, and no interaction effects (p ≥ 0.21) observed. Conclusions Follow-up data (e.g., interviews, focus groups, etc.) determining why differences in ADH and RET are observed appears prudent. To convert those that lapsed and/or abandoned SIH/PA into committed long-term PA adherers. This would be a first step to develop targeted public health promotions and initiatives to enhance health outcomes at a population level.
Collapse
Affiliation(s)
- Bryna C. R. Chrismas
- Department of Physical Education, College of Education, Qatar University, Doha, Qatar,*Correspondence: Bryna C. R. Chrismas
| | - Lina Majed
- Department of Physical Education, College of Education, Qatar University, Doha, Qatar
| | - Abdulla Saeed Al-Mohannadi
- World Innovation Summit for Health, Qatar Foundation, Doha, Qatar,Aspetar Orthopedic and Sports Medicine Hospital, Doha, Qatar
| | - Suzan Sayegh
- Aspetar Orthopedic and Sports Medicine Hospital, Doha, Qatar
| |
Collapse
|
10
|
Hermassi S, Bragazzi NL, Majed L. Body Fat Is a Predictor of Physical Fitness in Obese Adolescent Handball Athletes. Int J Environ Res Public Health 2020; 17:ijerph17228428. [PMID: 33202549 PMCID: PMC7696105 DOI: 10.3390/ijerph17228428] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 11/02/2020] [Accepted: 11/10/2020] [Indexed: 02/03/2023]
Abstract
We examined the relationships between body fat (BF) and field measures of physical fitness in adolescent handball players. Twenty nine players (age: 16.6 ± 1.72 years; body mass: 79.8 ± 17.0 kg; height: 1.70 ± 0.12 m; body fat: 27.7 ± 8.67%) from Qatar handball first league performed a series of anthropometric and fitness tests related to their performance in sprinting (i.e., 15 m and 30 m sprint), jumping (i.e., countermovement and squat jumps), throwing (i.e., 3 kg medicine ball seated front throw) and running (i.e., agility T-Half and Yo-Yo intermittent recovery level 1 tests). Significant differences between obese and non-obese groups, classified based on age-stratified %BF norms, were found, with the largest difference being attributed to aerobic performance on the Yo-Yo test. Results indicated no significant relationships between anthropometric variables and sprinting or jumping abilities. %BF predicted a significant 8–15% portion in running performances of agility and aerobic capacity, while the latter were mainly explained by body height and mass. %BF was the only and strongest predictor of throwing performance, being an important determinant of performance in handball. Optimizing %BF should be considered as a training and nutrition goal in order to improve sport performance.
Collapse
Affiliation(s)
- Souhail Hermassi
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha 2713, Qatar;
- Correspondence:
| | - Nicola Luigi Bragazzi
- Postgraduate School of Public Health, Department of Health Sciences (DISSAL), 16132 Genoa, Italy; or
- Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, ON M3J 1P3, Canada
| | - Lina Majed
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha 2713, Qatar;
| |
Collapse
|
11
|
Bawadi H, Alkhatib D, Abu-Hijleh H, Alalwani J, Majed L, Shi Z. Muscle Strength and Glycaemic Control among Patients with Type 2 Diabetes. Nutrients 2020; 12:E771. [PMID: 32183393 PMCID: PMC7146340 DOI: 10.3390/nu12030771] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 03/08/2020] [Accepted: 03/09/2020] [Indexed: 12/25/2022] Open
Abstract
Poor glycaemic control is associated with chronic life-threatening complications. This cross-sectional study examined whether there is an association between handgrip strength and glycaemic control among patients with diabetes. Data on 1058 participants aged 40 and older were collected from the National Health and Nutritional Examination Survey (NHANES). Muscle strength was assessed using a handgrip dynamometer, and glycaemic control was assessed using HbA1c. Handgrip strength was presented as age- and gender-specific quartiles, with participants in quartile 1 having the lowest handgrip strength and participants in quartile 4 having the highest handgrip strength. Logistic regression analyses were used to assess the association between handgrip strength and poor glycaemic control among participants with diabetes. Three models, each adjusted to include different variables, were employed. Odds ratio (OR) values revealed no association between handgrip strength and glycaemic control after adjusting for age, gender, and race in model 1. With further adjustment for sedentary activity, income-to-poverty ratio, education, and smoking, patients in quartile 4 of handgrip strength had 0.51 odds of poor glycaemic control (95% CI: 0.27-0.99). However, the reported association above vanished when further adjusted for insulin use (OR = 0.67; 95% CI: 0.35-1.28). In conclusion, findings may indicate an association between glycaemic control and muscle strength. This association may be altered by insulin use; further investigations are required.
Collapse
Affiliation(s)
- Hiba Bawadi
- Human Nutrition Department, College of Health Sciences, QU-Health, Qatar University, Doha 2713, Qatar; (D.A.); (H.A.-H.); (J.A.); (Z.S.)
| | - Dana Alkhatib
- Human Nutrition Department, College of Health Sciences, QU-Health, Qatar University, Doha 2713, Qatar; (D.A.); (H.A.-H.); (J.A.); (Z.S.)
| | - Haya Abu-Hijleh
- Human Nutrition Department, College of Health Sciences, QU-Health, Qatar University, Doha 2713, Qatar; (D.A.); (H.A.-H.); (J.A.); (Z.S.)
| | - Joud Alalwani
- Human Nutrition Department, College of Health Sciences, QU-Health, Qatar University, Doha 2713, Qatar; (D.A.); (H.A.-H.); (J.A.); (Z.S.)
| | - Lina Majed
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha 2713, Qatar;
| | - Zumin Shi
- Human Nutrition Department, College of Health Sciences, QU-Health, Qatar University, Doha 2713, Qatar; (D.A.); (H.A.-H.); (J.A.); (Z.S.)
| |
Collapse
|
12
|
Abstract
Background Physical inactivity is high within the Qatari population, particularly within females, and school-based environments, contributing to increased morbidity and mortality. School-based physical activity (PA) outcomes may be mediated by physical self-concept. Low physical self-concept may negatively impact PA engagement, compromising childhood and adolescent physical fitness, which may translate into adulthood. Normative physical fitness data for the Qatari population is unavailable. Stratifying normative physical fitness appears prudent, to not only allow comparisons to be made worldwide, but enable informed decisions for public health policy and future interventions in the Qatari population. Purpose To establish the physical fitness of young adults in Qatar, and examine differences between males and females for physical self-concept, and engagement in school-based and extra-curricular PA. Method 186 (females n = 85) healthy participants [median (minimum—maximum) age: males = 21 (18–26), females = 21 (18–24) y; height: males = 1.74 (1.57–1.99), females = 1.61 (1.46–1.76) m; body mass: males = 71.9 (49.3–145.0), females = 56.8 (35.7–96.4) kg] completed the ALPHA-FIT test battery for adults (one leg stand, figure of eight run, handgrip strength, jump and reach, modified push-up, dynamic sit-up and 2 km walk), physical self-description questionnaire (measuring physical self-concept), and were asked to answer ‘yes’ or ‘no’ to whether they participated in school-based and extra-curricular PA. Results Data is reported as effect size; ±90% confidence limit. Males compared to females most likely performed better for dynamic sit-up (2.2; ±0.76), very likely better for the figure of eight run (0.86; ±0.42) and likely better for handgrip strength (2.1; ±0.75). Males likely had higher physical self-concept for coordination (0.78; ±0.37) and endurance (0.66; ±0.27) compared to females. There were no differences for school-based PA (p ≥ 0.78) or for extra-curricular PA for males (p ≥ 0.26) or females (p ≥ 0.21). Conclusion The data suggests that the young Qatari adult population has variable, yet generally low, physical fitness traits compared to individuals worldwide, likely due to their low PA. The precise aetiology for this is not well documented, yet such data may be prudent to evidence-inform strategies to improve physical fitness through increased PA (synergistic relationship), given the strong association between physical activity/fitness and morbidity/mortality.
Collapse
Affiliation(s)
- Bryna C. R. Chrismas
- Qatar University, Sport Science Program, College of Arts and Science, Doha, Qatar
- * E-mail:
| | - Lina Majed
- Qatar University, Sport Science Program, College of Arts and Science, Doha, Qatar
| | - Zsuzsanna Kneffel
- Qatar University, Sport Science Program, College of Arts and Science, Doha, Qatar
| |
Collapse
|
13
|
Jabbour G, Majed L. Factors Associated to Mechanical Efficiency among Adolescent Boys Performing a Graded Maximal Exercise. Med Sci Sports Exerc 2019. [DOI: 10.1249/01.mss.0000560788.72398.9f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
Jabbour G, Majed L. Mechanical Efficiency at Different Exercise Intensities Among Adolescent Boys With Different Body Fat Levels. Front Physiol 2019; 10:265. [PMID: 30930799 PMCID: PMC6428771 DOI: 10.3389/fphys.2019.00265] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2018] [Accepted: 02/28/2019] [Indexed: 11/20/2022] Open
Abstract
This study investigated the mechanical efficiency (ME) and associated factors in obese, overweight, and normal-weight adolescent boys during incremental cycle exercise test to exhaustion. Forty-five sedentary adolescent boys (13–14 years old) were separated in three groups according to the percentage of fat mass as follows: 15 normal-weight (NW) (body fat: 16.0 ± 1.9%), 15 overweight (OW) (body fat: 24.0 ± 1.6%), and 15 obese (OB) (body fat: 31.0 ± 3.0%). All groups completed an incremental cycle exercise to exhaustion in which energy consumption (E, W), ME (%), lipid oxidation rate (LO, %), plasma epinephrine and norepinephrine concentrations were determined consecutively at rest and at three intensity levels corresponding to 50 and 75% of each participant’s maximal heart rate (50%HRmax and 75%HRmax) and peak oxygen consumption (V˙O2peak). During the incremental cycle exercise test, plasma epinephrine, and norepinephrine responses as well as ME determined at 50%HRmax, 75%HRmax, and at VO2peak stages were significantly lower in OB compared to NW and OW individuals (ps < 0.01). Multiple linear regressions showed that body weight (ß = -0.64, p < 0.001), energy consumption (ß = -0.24, p < 0.05) and lipid oxidation (ß = 0.69, p < 0.01) were significant predictors of ME at 50%HRmax. However, at 75%HRmax and V˙O2peak, significant predictors of ME were epinephrine (ß = 0.34, ß = 0.49, respectively, ps = 0.01), norepinephrine (ß = 0.26, ß = 0.60, respectively, ps < 0.05) and power output (ß = 0.62, ß = 0.71, respectively, ps < 0.01). These findings suggest that excess in body weight exerts a negative effect on ME at a low intensity by increasing energy consumption for obese and overweight adolescent boys, while at higher intensities (75%HRmax and VO2peak) the lower ME could be better explained by the lower power output and catecholamine responses that were attenuated among obese and overweight adolescent boys.
Collapse
Affiliation(s)
- Georges Jabbour
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha, Qatar
| | - Lina Majed
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha, Qatar
| |
Collapse
|
15
|
Briki W, Majed L. Adaptive Effects of Seeing Green Environment on Psychophysiological Parameters When Walking or Running. Front Psychol 2019; 10:252. [PMID: 30809177 PMCID: PMC6379348 DOI: 10.3389/fpsyg.2019.00252] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Accepted: 01/25/2019] [Indexed: 11/15/2022] Open
Abstract
Several studies have investigated the influence of perceiving colors on affective outcomes and/or performance. However, the effects of seeing colors on self-selected behaviors have received little attention from physiologists and psychologists. Therefore, the present study aimed at examining whether exposure to green and red environments could influence affective judgments, perception of effort, heart rate, and gait speeds when walking and running at a self-selected pace. Participants were randomly assigned to one of the three experimental conditions: Green, red, or white (neutral) environment. The experimental task consisted in a 20-min trial of either walking (Study 1) or running (Study 2) at the most comfortable speed on a treadmill surrounded by three large HD TV screens displaying specific properties of the studied colors. Study 1 revealed that walking in a green environment induced a significant reduction in heart rate values as compared to the red and white conditions although no differences in gait speed were found. This corroborates the calming and relaxing effect of green on the human organism. Study 2 showed that running in a green environment was associated with an increased level of perceived exertion at similar speeds (compared to other color conditions), while exposure to red induced a significant decrease in the level of tension. In both studies, the preferred gait speed was not affected by the colored environment which is discussed in relation to the energy-conservation principle. Furthermore, both studies showed that performing a 20-min walk or run at preferred pace presented beneficial mood changes. Implications of the effects of self-selected exercise under colored environments on human functioning are addressed in the discussion.
Collapse
Affiliation(s)
- Walid Briki
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha, Qatar
| | - Lina Majed
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha, Qatar
| |
Collapse
|
16
|
Jabbour G, Majed L. Ratings of Perceived Exertion Misclassify Intensities for Sedentary Older Adults During Graded Cycling Test: Effect of Supramaximal High-Intensity Interval Training. Front Physiol 2018; 9:1505. [PMID: 30410450 PMCID: PMC6209962 DOI: 10.3389/fphys.2018.01505] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Accepted: 10/05/2018] [Indexed: 11/17/2022] Open
Abstract
The present study aims (1) to evaluate ratings of perceived exertion (RPE) and corresponding intensities during a maximal graded cycling test and (2) to determine the effects of 6 weeks of supramaximal cycling exercise (SCE) intervention on RPE and associated physiological factors in young and older sedentary groups. Two healthy groups of 17 young adults [average (SD) age: 26.2 (2.4) year] and 13 older adults [average (SD) age: 54.5 (2.3) year] completed a 6-week SCE intervention on an ergocycle. Physiological values and RPE were collected across stages corresponding to ventilator thresholds 1 (VT1) and 2 (VT2) of the graded cycling test and 10 min following the end of test and during the six bouts of SCE. The relative intensity for both VT1 and VT2 were also objectively calculated based on the percent of maximal heart rate %HRmax and peak oxygen consumption %V˙O2peak. Before SCE intervention, RPE values were significantly higher for the older group compared to younger at VT1 [p < 0.01] and VT2 [p < 0.01], although both groups were working at similar relative intensities (%V˙O2). After 6 weeks of SCE, the older group’s perceived effort values were normalized to the actual estimated ones and were similar to those observed in younger individuals. The intervention elicited physiological changes at rest and submaximal intensities, while no improvements were noted for both groups in aerobic fitness (i.e., V˙O2peak). For both groups, RPE decreases with SCE at 10 min following graded test correlated significantly to V˙O2 (r = 0.61, p < 0.01). Our study revealed that the initial over-estimation of the exertion levels found for the older sedentary group at the tested submaximal intensities was no longer present after 6 weeks of SCE training, therefore matching RPE values of the young group and those estimated by %HRmax and %V˙O2peak methods. Therefore, combining the RPE method with other commonly used methods of estimating exercise intensity is highly recommended for sedentary older adults to suitably monitor the exercise intensity.
Collapse
|
17
|
Martinelli J, Habes D, Majed L, Guettier C, Gonzalès E, Linglart A, Larue C, Furlan V, Pariente D, Baujard C, Branchereau S, Gauthier F, Jacquemin E, Bernard O. Long-term outcome of liver transplantation in childhood: A study of 20-year survivors. Am J Transplant 2018; 18:1680-1689. [PMID: 29247469 DOI: 10.1111/ajt.14626] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Revised: 11/30/2017] [Accepted: 12/05/2017] [Indexed: 01/25/2023]
Abstract
We report the results of a study of survival, liver and kidney functions, and growth with a median follow-up of 24 years following liver transplantation in childhood. From 1988 to 1993, 128 children underwent deceased donor liver transplantation (median age: 2.5 years). Twenty-year patient and graft survival rates were 79% and 64%, respectively. Raised serum aminotransferase and/or γ-glutamyl transferase activities were present in 42% of survivors after a single transplantation. Graft histology (35 patients) showed signs of chronic rejection in 11 and biliary obstruction in 5. Mean total fibrosis scores were 4.5/9 and 3/9 in patients with abnormal and normal serum liver tests, respectively. Glomerular filtration rate was <90 mL·min-1 in 35 survivors, including 4 in end-stage renal disease who were undergoing dialysis or had undergone renal transplantation. Median final heights were 159 cm for women and 172 cm for men; final height was below the target height in 37 patients. Twenty-year survival after childhood liver transplantation may be close to 80%, and final height is within the normal range for most patients. However, chronic kidney disease or altered liver biochemistries are present in over one third of patients, which is a matter of concern for the future.
Collapse
Affiliation(s)
- J Martinelli
- Hépatologie pédiatrique and centre de référence national de l'atrésie des voies biliaires, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France
| | - D Habes
- Hépatologie pédiatrique and centre de référence national de l'atrésie des voies biliaires, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France
| | - L Majed
- Biostatistique et épidémiologie, Gustave Roussy, Villejuif, France
| | - C Guettier
- Anatomie pathologique, Hopital Paul Brousse-Bicetre, AP-HP, Inserm U 1193, Hopital Paul Brousse, Villejuif, France
| | - E Gonzalès
- Hépatologie pédiatrique and centre de référence national de l'atrésie des voies biliaires, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France.,Inserm U 1174, Hepatinov, Université Paris-Sud, Orsay, France
| | - A Linglart
- Department of pediatric endocrinology, APHP, Reference center for rare disorders of the mineral metabolism, and Plateforme d'Expertise Maladies Rares Paris-Sud, Le Kremlin Bicêtre, France.,INSERM U1169, Hôpital Bicêtre, Le Kremlin Bicêtre, France.,Université Paris-Saclay, Orsay, France
| | - C Larue
- Biostatistique et épidémiologie, Gustave Roussy, Villejuif, France
| | - V Furlan
- Toxicologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
| | - D Pariente
- Radiologie pédiatrique, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
| | - C Baujard
- Anesthésie réanimation chirurgicale, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
| | - S Branchereau
- Chirurgie pédiatrique, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France
| | - F Gauthier
- Chirurgie pédiatrique, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France
| | - E Jacquemin
- Hépatologie pédiatrique and centre de référence national de l'atrésie des voies biliaires, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France.,Inserm U 1174, Hepatinov, Université Paris-Sud, Orsay, France
| | - O Bernard
- Hépatologie pédiatrique and centre de référence national de l'atrésie des voies biliaires, Hôpital Bicêtre, AP-HP and Université Paris-Sud, Le Kremlin-Bicêtre, France
| |
Collapse
|
18
|
Selmi O, Haddad M, Majed L, Ben Khalifa W, Hamza M, Chamari K. Soccer training: high-intensity interval training is mood disturbing while small sided games ensure mood balance. J Sports Med Phys Fitness 2017; 58:1163-1170. [PMID: 28488826 DOI: 10.23736/s0022-4707.17.07292-9] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND The aim of the study was to compare the effects of high-intensity intermittent training (HIIT) versus small-sided games (SSG) in soccer on both the physiological responses and the mood state of players. METHODS Sixteen professional soccer players took part in the study (age: 24.1±0.9 years). Testing of players was conducted on separate days in a randomized and counter-balanced order (each training session: 28 minutes: 4x4 minutes work with 3 minutes of passive recovery in-between). Effort: HIIT: intermittent 15-s runs at 110% maximal aerobic speed with 15 seconds of passive recovery in-between. SSG: 4 versus 4 players on a 25x35 meter pitch size with full-involvement play. Psychological responses before and after each training-session were assessed using the profile of mood-state (POMS: Tension, Depression, Anger, Vigor, Fatigue, and Confusion). The players' heart rate (HR) was continuously measured, whereas ratings of perceived exertion (RPE) and blood lactate concentration ([La]) were collected ~3-min after each training-session. RESULTS HIIT and SSG showed no significant difference in HR, RPE and [La] responses. The HIIT compared with SSG resulted in: an increased total mood disturbance (P<0.001), tension (P<0.05), fatigue (P<0.01) and a decreased vigor (P<0.001). CONCLUSIONS Both HIIT and SSG sessions induced similar physiological responses, in contrast, HIIT produced a mood disturbance while SSG ensured mood balance. Practitioners could choose between these two exercises according to the objective of their training, keeping in mind the mood-related advantages of the SSG shown in the present study.
Collapse
Affiliation(s)
- Okba Selmi
- Sportive Performance and Physical Rehabilitation, High Institute of Sport and Physical Education, University of Jandouba, Kef, Tunisia.,Faculty of Sciences of Bizerte, University of Carthage, Zarzouna, Bizerte, Tunisia
| | - Monoem Haddad
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha, Qatar -
| | - Lina Majed
- Sport Science Program, College of Arts and Sciences, Qatar University, Doha, Qatar
| | - Wissam Ben Khalifa
- Sportive Performance and Physical Rehabilitation, High Institute of Sport and Physical Education, University of Jandouba, Kef, Tunisia
| | - Marzougui Hamza
- Sportive Performance and Physical Rehabilitation, High Institute of Sport and Physical Education, University of Jandouba, Kef, Tunisia
| | - Karim Chamari
- Athlete Health and Performance Research Center, ASPETAR, Qatar Orthopedic and Sports Medicine Hospital, Doha, Qatar
| |
Collapse
|
19
|
Hansen C, Wei Q, Shieh JS, Fourcade P, Isableu B, Majed L. Sample Entropy, Univariate, and Multivariate Multi-Scale Entropy in Comparison with Classical Postural Sway Parameters in Young Healthy Adults. Front Hum Neurosci 2017; 11:206. [PMID: 28491029 PMCID: PMC5405138 DOI: 10.3389/fnhum.2017.00206] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2016] [Accepted: 04/07/2017] [Indexed: 12/02/2022] Open
Abstract
The present study aimed to compare various entropy measures to assess the dynamics and complexity of center of pressure (COP) displacements. Perturbing balance tests are often used in healthy subjects to imitate either pathological conditions or to test the sensitivity of postural analysis techniques. Eleven healthy adult subjects were asked to stand in normal stance in three experimental conditions while the visuo-kinesthetic input was altered. COP displacement was recorded using a force plate. Three entropy measures [Sample Entropy (SE), Multi-Scale Entropy (MSE), and Multivariate Multi Scale Entropy (MMSE)] describing COP regularity at different scales were compared to traditional measures of COP variability. The analyses of the COP trajectories revealed that suppression of vision produced minor changes in COP displacement and in the COP characteristics. The comparison with the reference analysis showed that the entropy measures analysis techniques are more sensitive in the incremented time series compared to the classical parameters and entropy measures of original time series. Non-linear methods appear to be an additional valuable tool for analysis of the dynamics of posture especially when applied on incremental time series.
Collapse
Affiliation(s)
- Clint Hansen
- Research Department, Aspetar Qatar Orthopaedic and Sports MedicineDoha, Qatar
| | - Qin Wei
- School of Information Engineering, Wuhan University of TechnologyWuhan, China
| | - Jiann-Shing Shieh
- Department of Mechanical Engineering, Yuan Ze UniversityChung-Li, Taiwan
| | - Paul Fourcade
- URCIAMS - Motor Control and Perception Team, University Paris-SudOrsay, France
| | - Brice Isableu
- PSYCLE, Aix Marseille UniversityAix-en-Provence, France
| | - Lina Majed
- Sport Science Program, College of Arts and Science, Qatar UniversityDoha, Qatar
| |
Collapse
|
20
|
Majed L, Heugas AM, Chamon M, Siegler I. Learning an energy-demanding and biomechanically constrained motor skill, racewalking: Movement reorganization and contribution of metabolic efficiency and sensory information. Hum Mov Sci 2012; 31:1598-614. [DOI: 10.1016/j.humov.2012.06.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2012] [Revised: 05/30/2012] [Accepted: 06/23/2012] [Indexed: 10/27/2022]
|